Sernova Corp. (SVA.TO) TSX

Currency In CAD

AD

Sernova Corp.

Address

The Stiller Centre

London, ON N6G 4X8

United Kingdom of Great Britain and Northern Ireland (the)

Phone

519 858 5184

Sector

Healthcare

Industry

Biotechnology

Employees

17

First IPO Date

April 29, 1999

Key Executives

NameTitlePayYear Born
Jonathan N. RigbyPresident, CEO & Director980,6131968
David BurkeVice President of Investor Relations163,151N/A
Pericles CaliasChief Development Officer and Head of R&D336,2961968
James T. ParsonsChief Financial Officer471,9001965
Marylyn RigbyChief Communications Officer521,125N/A
AD

Description

Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.

AD